HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS.
Ithimakin S, et al. Among authors: day ml, day kc.
Cancer Res. 2013 Mar 1;73(5):1635-46. doi: 10.1158/0008-5472.CAN-12-3349. Epub 2013 Feb 26.
Cancer Res. 2013.
PMID: 23442322
Free PMC article.